Please login to the form below

Not currently logged in
Email:
Password:

Concordia

This page shows the latest Concordia news and features for those working in and with pharma, biotech and healthcare.

Concordia accused of overcharging NHS for thyroid drug

Concordia accused of overcharging NHS for thyroid drug

Concordia accused of overcharging NHS for thyroid drug. The pharma firm said to have ‘abused’its position within the UK market. ... Markets Authority (CMA), which says Concordia “abused its dominant position to overcharge the NHS”.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Transformational deals. The two largest deals announced this month were Cinven's sale of Amdipharm Mercury (AMCo) to Concordia Healthcare and Actelion's move to acquire ZS Pharma, at $3.5bn ... level. AMCo's commercial footprint reaches across 100

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    J&J divest subsidiary marketing vascular devices. 1, 944. Covis / Concordia.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Covis (asset). Concordia. 1.2. 8.2. NR. Hyperion. Horizon. 1.1. 9.6. 35%.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    341. Revive Pharmaceuticals/ Concordia Healthcare. Product acquisition. Donnatal, adjunctive therapy for IBS and acute enterocolitis (marketed).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics